News | September 02, 2014

John Muir Health's Concord Medical Center First in Northern California to Use the FIRMap to Treat AFib

topera, catheter, FIRMmap

September 2, 2014 – John Muir Health's Concord medical center is the first hospital in Northern California and one of just 20 hospitals in the nation to begin treating patients who suffer from atrial fibrillation (AFib), the most common type of heart arrhythmia, with a new procedure that features the FDA cleared FIRMap Catheter.

A heart arrhythmia refers to the disorganization of the electrical impulses in the heart causing an irregular or rapid beat. AFib is an abnormal heart condition affecting more than 2.5 million Americans (more than the population of San Francisco, San Jose and Oakland combined) and is considered one of the most common arrhythmia problems in adults over the age of 65. Left untreated, atrial fibrillation can lead to serious consequences such as heart failure or stroke.

"To successfully treat AFib, the actual source must be identified, as well as the triggering cells. The exact areas in the upper chamber of the heart responsible for maintaining fibrillation have historically proven to be elusive resulting in a lower success rate than desired and creating frustration for patients and physicians," said Susan Eisenberg, M.D., cardiac rhythm center medical director at John Muir Health. "Using the FIRMap Catheter and 3-D mapping technology, the treatment results are far beyond any medication or surgical procedure previously available. We can now pinpoint the patient-specific source of arrhythmia with accuracy, which is critical as it allows us to address the cause of AFib in a single procedure with a very high rate of success."

Clinical trials showed that 82.4 percent of patients treated using the FIRMap Catheter and 3-D mapping technology were free of AFib after a single procedure versus 44.9 percent of those treated with the standard pulmonary vein isolation (PVI) approach. After three years, 77.8 percent of patients treated with the FIRM technology were free of AFib compared to 38.5 percent treated with the PVI approach.

"Previously, the treatment options were limited to a one-size fits all approach, which had a much lower success rate and, therefore, would need to be repeated," said Eisenberg. "Undergoing the procedure again is inconvenient for patients, means they still are living with AFib, increases their number of doctor visits and raises health care costs."

John Muir Health has performed the new procedure on 30 patients thus far with excellent results. Suzan Pemberton of Lafayette, Calif., recently had her AFib treated using the FIRMap catheter and 3-D mapping system.

"I only recently found out that I had AFib," said Pemberton. "This new treatment technology gives me peace of mind that the source has been found, it has been corrected and I can continue to travel and live my normal life."

The FIRMap catheter, developed by Topera Inc., is an innovative medical device that allows doctors to view specific areas in the heart, which could sustain an arrhythmia. This device, along with a ground-breaking 3-D mapping system, has become essential when performing the progressive procedure known as FIRM Guided ablation, which strives to detect and neutralize the source of electrical impulses or "rotors" disrupting the heart’s normal rhythm. Using this technology, the ablation procedure can target a patient-specific area of the heart, which is critical to that patient’s arrhythmia. The precision of the procedure ultimately aims to diminish recurrence rates among patients, thus generating a major feat in arrhythmia technology today.

For more information: www.johnmuirhealth.com

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Overlay Init